-- 布依格电信(Bouygues Telecom,隶属于布依格集团 (EN.PA, ENNV.PA))、法国电信 (Orange,ORA.PA) 和 Free-iliad 集团已提交新的收购要约,拟以 203.5 亿欧元的企业价值收购 Altice France 旗下的 SFR 电信业务。目前,三家公司已准备就此展开独家谈判。 消息公布后,截至周五中午,布依格和法国电信的股价在巴黎分别下跌超过 1% 和近 4%。 Altice France 当天发布的联合声明显示,已授予由三家法国电信公司组成的财团独家谈判期,截止日期为 5 月 15 日,以便最终敲定对其 SFR 电信业务的收购。此次最新报价较 Altice 于 2025 年 10 月提出的 170 亿欧元初始报价有所提高,该报价已被 Altice 拒绝。 这项拟议交易是在2026年启动的尽职调查阶段之后提出的,交易内容包括Altice France-SFR运营的大部分资产,但不包括部分股权以及Altice France在法国海外省和地区的业务。 该财团将平分收购价格和价值,其中布依格电信(Bouygues Telecom)承担42%,Orange承担27%,Free-iliad承担剩余的31%。预计该交易将有助于维持和加强法国的数字经济及其电信行业。 AlphaValue/Baader Europe的分析师在一份报告中指出:“此次收购对布依格和Orange有利,因为它将使法国的电信运营商数量从4家减少到3家。值得注意的是,与首次报价相比,额外增加的33.5亿欧元对Orange集团而言仅相当于约9亿欧元。” 该财团谨慎地表示,新提议能否最终达成协议尚无定论。此外,该交易仍需获得监管部门的批准,并与相关员工代表机构进行磋商。
Related Articles
Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23
AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%
Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision
Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.